News for Innate Pharma S.A. (IPHA)

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced that members of its executive team w

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) announced the voting results of its shareholders at

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced the presentation of long-term follow

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) announced today that four abstracts with Innate's dr

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced that an abstract regarding IPH6501,

Innate Pharma (IPH, IPHA) is set to present abstracts on its ANKET® platform at the EHA Congress 2025. The company highlights IPH6501's potential in tr

The following slide deck was published by Innate Pharma S.A.

Innate Pharma S.A. (NASDAQ:IPHA) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ETCorporate ParticipantsHenry Wheeler - VP, IR and...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today reported its consolidated financial results fo

Regulatory News: Pursuant to the article L. 233-8 II of the French ”œCode de Commerce” and the article 223-16 of the French stock-market authorities (Autor

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”), today announced that the Company will hold a confer

- Innate Pharma (IPHA) will host a conference call on May 13, 2025, to discuss Q1 2025 business updates. - The call will feature key executives and is accessibl

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announced the filing of its 2024 Universal Reg

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today shared new preclinical data for IPH4502, its n

Regulatory News: Pursuant to the article L. 233-8 II of the French ”œCode de Commerce” and the article 223-16 of the French stock-market authorities (Autor

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announces a €14,999,998.59 capital increase

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (”œInnate” or the ”œCompany”) today announce review of their January 2016 Research

\nRegulatory News:\n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) today announced it will propose to its Annual Genera

\nRegulatory News: \n\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (â\u0080\u009cInnateâ\u0080\u009d or the â\u0080\u009cCompanyâ\u0080\u009d) will hold its annual general meeting of shareholder